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   ENDOCRINOLOGISTS 
ATA   - AMERICAN  THYROID  ASSOCIATION 
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INTRODUCTION 
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INTRODUCTION 
It has been long recognized that thyroid dysfunction may have 
profound effects on the female reproductive system. A relationship 
between  the thyroid gland and the gonads is suggested by far more 
frequent occurrence of thyroid disorders in women than in men by clinical 
appearance of goitre during pregnancy, puberty and menopause. Thyroid 
disorders are 10 times more common in women than in men (47). Currently 
subclinical thyroid dysfunction is  on  the  rising  side  than  overt  
dysfunction. 
The effect of thyroid hormones  is due  to the  direct metabolic 
effects on the gonads as well as indirectly through alterations in anterior 
pituitary hormones that control the sexual functions.(9) 
Regular menstruation is a feature of contemporary society. Large 
family size, prolonged breast feeding and reduced life expectancy limited 
the number of cycles experienced by women in the past. Currently women 
may experience more than 400 menstruations between menarche and 
menopause. 
One of the common causes of women attending gynecology OPD is 
abnormal uterine bleeding constituting  around 30 percentages. Majority of 
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women who present with bleeding problems, no underlying abnormality 
could be made out. It is quite often this situation tackled with fractional 
curettage and finally hysterectomy. 
AUB encompasses a wide spectrum of disorders such as 
reproductive tract diseases, systemic diseases and iatrogenic causes. 
Thyroid dysfunction accounts for 30% -  40% of  cases in systemic 
disorders causing AUB. 
The goal of evaluation of AUB is to arrive at an accurate and 
clinically useful diagnosis in the most efficient and cost effective manner 
possible. Thyroid function test is helpful in women presenting with AUB 
to detect subclinical conditions and provide an opportunity to treat the 
cause. This will avoid unnecessary hormonal treatment, surgery and reduce 
patient morbidity. 
 
 
 
 
 
AIM OF THE STUDY 
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AIM OF THE STUDY 
1. To determine the association between menstrual irregularities and 
thyroid dysfunction. 
2. To analyze the pattern of menstrual dysfunction among women with 
thyroid disorder. 
3. To estimate the prevalence of subclinical thyroid diseases among 
women  in the  reproductive age group with abnormal uterine bleeding. 
4. To establish if screening for thyroid abnormalities is justified using 
T3,T4,TSH. 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
ABNORMAL UTERINE BLEEDING (58) 
 Any bleeding from the genital tract which is a deviation from the 
normal in frequency , cyclicity and quantity. 
 The average duration of menstrual cycle is 28 days (21 – 35 days), 
duration of bleeding varies from (2-8 days) and mean menstrual blood loss 
is about 30 – 40 ml. 
TYPES OF AUB (58) 
1. Menorrhagia – Cyclical bleeding at normal and regular intervals,    
excessive in amount  (More than 80ml) and duration (more than 5 
days )or both. 
2. Polymenorrhoea – Cyclical bleeding at frequent intervals (less than 
21 days), normal in amount. 
3. Hypomenorrhoea – Menstrual bleeding scanty on amount (less than 
2 days) 
4. Oligomenorrhoea – Menstrual bleeding more than 35 days and 
remains constant  at  that  frequency. 
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5. Amenorrhoea – Absence of periods in a total of atleast three of 
previous  three cycle  intervals or months. 
6. Metorrhagia – irregular cyclical bleeding. 
7. Polymenorrhagia – cyclical bleeding which is both excessive and 
frequency. 
DYSFUNCTIONAL UTERINE BLEEDING (DUB) 
Abnormal uterine bleeding for which no organic cause can be found. 
This is a diagnosis of exclusion. 
CAUSES OF AUB IN REPRODUCTIVE AGE (58) 
Pregnancy  and  related conditions: 
- Ectopic pregnancy 
- Abortions 
- Trophoblastic diseases 
Medications and Iatrogenic Causes: 
- Anticoagulants 
- Corticosteroids 
- Antipsychotics 
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- Oral contraceptive pills (progestin only pills)  
- Selective Serotonin Receptor Inhibitors 
Systemic disorders: 
- Adrenal hyperplasia and cushing’s diseases. 
- Blood dyscrasias 
- Coagulopathies 
- Hepatic disorder 
- Thyroid disorder 
Genital Tract Pathology 
(a)  Infections 
- Cervicitis,  Myometritis,  Endometritis 
- Tuberculosis 
- Salpingitis 
(b) Benign Conditions 
- Adenomyosis 
(c) Malignant Conditions 
- Cervical  cell carcinoma 
- Endometroid adenocarcinoma 
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- Leiomyosarcoma 
- Testosterone  producing  ovarian  tumours 
(d) Trauma to genital tract 
(e) Foreign body adhesions and lacerations. 
 A brief outline of physiology of menstruation and thyroid function is 
essential for better understanding of abnormal uterine bleeding caused by 
thyroid dysfunction. 
PHYSIOLOGY OF MENSTRUATION AND OVULATION:(47) 
- Hypothalamo – pituitary – ovarian axis must be actively 
coordinated, endometrium  respond to ovarian hormones and the 
outlet tract must be patent for the menstruation to occur. 
- An estrogen dominated   preovulatory phase known as follicular (or) 
proliferative phase. 
- A progesterone dominated  and postovulatory phase  known as 
luteal phase (or) secretory phase. 
- Menstrual phase following progesterone withdrawal due to corpus 
luteum demise. 
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Follicular phase of menstrual cycle lasts for 10- 16 days. Luteal phase 
which is always constant lasts for 14 days. Estrogen responsible for 
proliferative changes and  endometrium  exposure to progesterone leads to 
secretory phase. 
Follicular  phase : 
 It starts with menstruation and ends by ovulation, characterized by 
development of ovarian follicles. During last few days of the menstrual 
cycle, decline in steroid production by corpus luteum leads to elevated 
FSH levels and this stimulates follicle development. Aromatase enzyme in 
granulosa cells converts androgen to estrogen activated by FSH, leads to 
increased estrogen level and increase in the number of granulosa cells 
noted ,as growth of the follicle. FSH stimulation also leads to LH receptor 
formation on granulosa cells which secretes small quantity of progesterone 
which exerts positive feedback on estrogen primed pituitary to augment 
LH release. LH stimulates androstenedione production in theca cells, 
aromatization of androgen to estrone and then to estrodiol by 17ȕ 
hydroxysteroid dehydrogenase Type I. This is known as regulation of two 
cell two  gonadotrophin  hypothesis. 
FSH recruit cohort of follicles from a pool of non-proliferating 
follicles on day 1-4 of menstrual cycle. Selection of one follicle occurs  on 
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5-7th day while other follicles undergo progressive atresia. By 8th day the 
selected follicle exerts dominance  hence  termed as dominant follicle, 
which later undergo maturation to form the Graffian follicle. 
  FSH levels are  elevated during early follicular phase and then 
begin to decline until ovulation. LH levels begins to increase by mid 
follicular phase. LH surge occurs due to positive feedback mechanism of 
increasing estrogen which triggers the  ovulation process. 
OVULATION  
 It occurs about 10 – 12 hours after a peak in LH levels and LH surge 
occurs 24 – 36 hours prior to ovulation, which stimulates luteinization of 
granulosa cells and there by synthesis of progesterone. It also stimulates 
resumption of meiosis. The amount of prostaglandins and proteolytic  
enzymes begins to  rise after an increase in progesterone and LH levels. 
 The Graffian follicle begins to enlarge at a rate of 1-2mm/day and 
attains a maximum size of about 20mm at ovulation time. The activated  
proteolytic enzymes and prostaglandin leads to an explosive release of 
oocyte-cumulus complex from the follicle by digesting the collagen in the 
follicular wall and stimulates smooth muscle  within the ovary to a certain 
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extent. After ovulation there is sudden shrinkage of follicular wall and free 
fluid in the  pouch of Douglas. 
Luteal Phase (Secretory Phase) 
 Granulosa cells increase in size continuously after ovulation. 
Luetinized  granulosa  cells with  theca interna cells constitute  the  corpus 
luteum. 
Main function of  the corpus luteum is to prepare the estrogen 
primed endometrium for implantation. It is a temporary endocrine organ. 
Secretory phase is  categorized into  
Early secretory phase  is regulated by both estrogen and 
progesterone. 
Mid Secretory phase is regulated by progesterone. 
Late secretory phase is mainly due to withdrawal of progesterone. 
Corpus luteal cells starts to proliferate and becomes vascularised 
under the influence of angiogenic factors secreted by granulosa and theca 
cells. The function of corpus luteum begins to decrease about 9-11 days 
after ovulation. Corpus luteum undergoes luteolysis and forms a scar tissue 
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known as corpus albicans in the absence of pregnancy. Corpus luteum 
demise leads to decrease in  LH levels and surge in the estrogen and PGF2. 
MENSTRUAL PHASE 
 Corpus luteum degeneration leads to decrease in estrogen and 
progesterone levels. Physiological withdrawal of progesterone gives rise to 
molecular and cellular interactions, finally resulting in menstrual bleeding. 
Progesterone withdrawal initiates synthesis of prostaglandins and COX-2 
resulting  in elevation of PGE2 and PGF2. Myometrial contractions and 
vasoconstriction due to PGF2 thereby produces sloughing of degraded 
endometrial tissue. 
 Estrogen stimulates regeneration of surface endometrial epithelium 
within 2 days after menstuation. Prolonged vasoconstriction due to 
estrogen secreted by the growing follicle, enables  formation of clot over 
the denuded endometrial vessels.  
THYROID  GLAND 
  Thyroid gland first described by Galen maintains tissue metabolism 
at the optimum level for normal function. It originates embryologically 
from an evagination of the pharyngeal epithelium with contributions from 
the lateral pharyngeal pouches. The thyroid is one of the largest endocrine 
organs weighing approximately about 25 grams. The thyroid is well 
vascularised  with an estimated blood flow ranging from 4-6ml/min/gram, 
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one of the highest flow rates in the body. Two lobes each 2.0 to 2.5cm in 
thickness and 4.0cm in length joined by isthmus constitute the thyroid.  
Synthesis of Thyroid hormones(51) 
 Synthesis of thyroid hormones depends on the entry of iodine into 
the thyroid, normal iodine metabolism and synthesis of receptor protein  
for iodine namely thyroglobulin. Inorganic iodide from the diet is actively 
transported into the thyroid cell and follicular lumen. Oxidation of iodide, 
effected by peroxidase, facilitates iodination of tyrosyl residues in 
thyroglobulin resulting in the formation of inactive precursors 
monoiodotyrosine (MIT) and diiodotyrosine (DIT).Iodothyronines(T3 and 
T4)  are formed by a coupling reaction of iodotyrosines occuring within 
thyroglobulin molecule and by oxidative condensation through peroxidase.  
Follicular colloid is pincytosed at the apical margin of the cells and fuses 
with thyroid lysosomes in which thyroglobulin is hydrolyzed by proteases 
and free thyroid hormones are released into the circulation. 
Thyroid Hormone turnover(51) 
 Normal T4 production rate is around100nmol/day. 80% of T3 and the 
entire r T3 are produced by metabolism of T4. Once released into the blood, 
T4 is bound to thyroid binding globulin (TBG), thyroid binding prealbumin 
and albumin. TBG is the major binding protein and only 0.03 percent of 
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circulating T4 is free. T3 is bound 10 to 20 times less firmly by TBG than 
T4. Consequently, the proportion of free T3 (0.3percent) is 8 to 10 times 
greater than that of T4.  T3 possesses high affinity for receptors in the 
tissues and hence, has a metabolic potency 3 to 5 times that of T4. Due to 
its relatively weak binding, T3 has a rapid onset and offset of action.  
Metabolism of thyroid hormones(51) 
 Following penetration into the cell, the iodothyronines undergo one 
of three metabolic transformations – deiodination ,conjugation and outside 
chain modifications. 
1. Deiodination is the most important route of metabolism and 
proceeds by sequential removal of single iodine atoms ultimately yielding 
the thyronine nucleus stripped of iodine. 70% of T4 and T3 disposal occurs, 
chiefly  in the liver and kidneys  through  deiodination . 
 One third of the circulating T4 is  converted to T3 and 45 percent is 
converted to r T3. T3 is produced by the removal of an iodine atom at the 5’ 
position of T4 by the action of 5’ – deiodinase. Three isoenzymes have 
been identified containing selenocysteine in the active centre.  
 Type I deiodinase present in the liver, kidney and thyroid effects the 
majority  of  T4 to  T3 conversation and also converts r T3 to  
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3,3’ - diodothyronine. Enzyme activity is increased in hyperthyroidism and 
decreased in hypothyroidism. A sulfhydryl containing cytosolic cofactor, 
possibly glutathione is required for deiodination. Type-1 deiodianase is 
inactive during  fetal  life and systemic illness. 
 Type 2 deiodinase (D2) is localized in the pituitary, central nervous 
system, placenta and brown fat. D2 activity increases in hypothyroidism 
allowing to maintain intracellular T3 concentrations in the brain and 
pituitary and physiological suppression of TSH release by T4 is dependent 
on D2 activity. 
 Type 3 deiodinase present in the placenta protects the foetus from 
maternal T3 and  T4. Inner ring deiodination of T4 by  D3 is  the  most  
important source of circulating r T3. 
2. Conjugation in the liver with glucuronate and sulfate accounts for 
20%  of T4 and T3 disposal with the conjugates secreted into the bile. 
3. Side chain modification by oxidative deamination and decarboxylation 
of the alanine side chain to yield tetraiodo and triiodothyroacetic acid 
accounts for 5 percent of daily disposal of thyroid hormones, 
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REGULATION OF THYROID FUNCTION(53) 
 Thyroid function is regulated by suprathyroidal and intrathyroidal 
mechanisms. Suprathyroid control is exerted through the hypothalamic – 
pituitary thyroid axis. Thyroid stimulating hormone (TSH) secreted by the 
anterior  pituitary binds to receptors on the follicular cells of the thyroid, 
activating adenylate cyclase and increasing cellular cyclic AMP leading to 
synthesis and secretion of thyroid hormones. 
 TSH secretion is regulated by two opposing influences on the 
pituitary thyrotrophs. Thyrotropin releasing hormone (TRH), a tripeptide 
produced by the hypothalamus, stimulates TSH  secretion while thyroid 
hormones both inhibit the TSH secretion directly by reduced expression of 
subunit genes and antagonize the action of TRH by reducing TRH 
production and the number of TRH receptors on the pituitary thyrotrophs. 
 The principal arbiter of thyroid hormone action in pituitary is T3 
derived from plasma as well as generated locally from intrapituitary T4 by 
type 2 deiodinase. 
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 Intrathyroid regulation is responsible for modifying the response to 
TSH by influencing production of cyclic AMP. This auto regulatory 
mechanism is based on changes in glandular organic iodine content. 
THYROID HORMONE INFLUENCE ON REPRODUCTIVE 
SYSTEM FETUS AND THE NEONATE:(9) 
 Fetal thyroid gland begins to synthesis thyroid hormones between 8 
– 10 weeks of gestation. No defects in the reproductive system in human 
studies are  notified in neonatal Grave’s diseases. Sexual maturation occurs 
earlier in animal studies in disease of   thyroid excess. 
 Small ovaries present in fetal hypothyroidism which are deficient in 
lipid and cholesterol are seen in animal studies. No effects are found in the 
reproductive system in human studies  especially  in hypothyroidism. 
Hypothyroidism and hyperthyroidism show no changes in fetal and 
neonatal period, even through animal studies show significant changes. 
PREPUBERTAL(44) 
 Sexual maturation is delayed when thyrotoxicosis occurs before 
puberty. In Mccune Albright syndrome coincidental association of 
thyrotoxicosis,  sexual precocity is noted   with  polystotic fibrous 
dysplasia.  
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 Juvenile hypothyroidism is mainly characterized  by  delay in onset 
of puberty and followed by  anovulatory cycles. Primary  hypothyroidism  
causes precocious sexual development and galactorrhoea. Paradoxically 
due to “spill over” of increased TSH which stimulates LH receptor, 
myxedematous infiltration of ovary may play a role (33).  
ADULT WOMEN 
Hypothyroidism(42) 
1.  Association with ovarian hyper stimulation syndrome especially in 
hypothyroidism. 
2.  Severe hypothyroidism is associated with diminished libido and 
failure of ovulation. 
3.  Menorrhagia occurs due to anovulation.  Inadequate progesterone  
secretion and endometrial proliferation continues, due to estrogen 
resulting  in irregular break through bleeding. 
4.  Rarely, ovarian atrophy and amenorrhoea occurs in primary 
hypothyroidism  due  to  secondary  depression  of  pituitary  
function. 
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5.  T4 has been found to enhance the action of gonadotrophins in 
leutinization and progestin secretion. 
6.  Granulosa cells also contains TSH receptors. 
Hyperthyroidism(42) 
1.  Raised levels of LH, FSH and estrogen. 
2.  Midcycle LH peak reduced or absent but gonatrophin response to 
GnRH is increased. 
3.  SHBG increases leads to decrease in clearance of testosterone and 
estradiol. 
4.  Peripheral aromatization of androgen to estrogen occurs due to 
alleviation of  peripheral blood flow. 
5.  Disruption occurs in amplitude and frequency of LH/FSH pulses 
due to thyroid  hormones  influencing  GnRH  signal 
PREGNANCY(49) 
  There is  a slight increase in the thyroid size due to increased 
circulating estrogen, and associated increase in the secretion of thyroid 
binding globulin levels due to elevated level of HCG, which has the 
inherent property of thyroid stimulating effects. 
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 Transient decrease in the TSH levels in early pregnancy found after 
that  within normal range and remain same or increase until parturition. 
Free T3 decreases throughout pregnancy. Free T4 remains constant but may 
increase in early pregnancy and then decrease slightly below normal levels 
than in non- pregnant controls. 
 In choriocarcinoma and hydatidiform mole, the placenta and 
trophoblastic tissue secretes substances with TSH activity  which is 
responsible for the  thyrotoxicosis.  
CLINICAL SYMPTOMS AND SIGNS OF THYROID DISORDER 
HYPOTHYROIDISM 
SYMPTOMS      SIGNS 
1. Cold intolerance      Bradycardia 
2. Weight gain      Hypertension 
3. Constipation      Hyperlipidemia 
4. Dryness of skin,coarseness of hair 
5.Menstrual  irregularities 
6.Decresed mental concenteration 
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HYPERTHYROIDISM 
SYMPTOMS      SIGNS 
1. Nervousness      Proptosis 
2. Disturbed sleep              Lid lag 
3. Palpitations             Tachycardia 
4. Sweating              Tremor 
5. Diarrhoea              Warm and Moist skin 
6. Heat intolerance              Goitre 
7. Weight loss 
THYROID FUNCTION TEST 
1.BMR MEASUREMENT(53) 
Tissue response (oxygen consumption) is measured by BMR  . 
This test has poor sensitivity and specificity.  
Previously used as thyroid function test, nowadays not preferred.  
Normal value ±20 percent. 
Hyperthyroidism elevated to 100 percent. 
Hypothyroidism declines to -30 to -40 percent. 
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2. PROTEIN BOUND IODINE ESTIMATION (53) 
It reflects the level of circulating T3 and T4 bound to the plasma protein. 
This test has poor sensitivity and specificity. 
Normal value 6gm/100ml. 
Increased  level  seen  in  hyperthyroidism, space  user. 
Decreased  level  seen in  hypothyroidism,  pregnancy and acute  
thyroiditis. 
3.RADIO ACTIVE IODINE UP TAKE(53) 
This test is performed by 25 curies radio active iodine I131  given  in 
100ml of water and thyroid up take is estimated by placing a x-ray counter 
over the neck. An area over the thigh is taken for count and final 
measurement is thigh count subtracted from neck count to correct for non 
thyroidal radio activity in neck.  
Normal value (at24hrs) - 20-40% 
Hyperthyroidism           - elevation to 60%  
Hypothyroidism             - less than 20% 
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4. FREE T3, T4, TSH LEVELS IN BLOOD(53) 
 This is best and widely used test. 
 It gives accurate measurement of thyroid levels. 
 Radio immuno assay or ELISA method used  
 Total T3 and T4 estimation has its drawbacks 
x The major portion which is bound and not taking part in 
metabolism . 
x Thyroid binding globulin alters the total hormone levels in 
conditions  like pregnancy. 
Free T3,  T4 truly  represent thyroid activity which is preferred over 
total T3 and T4.  
TSH levels is an important parameter of thyroid function which 
reflects the integrity of hypothalamic pituitary axis  
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NORMAL 
VALUES 
HYPERTHYROIDISM HYPOTHYROIDISM 
FREE 
T3 
2.3- 4.2 
pg/ml   
FREE 
T4 
0.8 – 2 
ng/dl   
SERUM  
TSH 
0.5-
5.0mIU/ml   
 
5.THYROID SCAN(53) 
 Radio nucleotide scan of thyroid  is performed  by either  Iodine131 
or Technectium 99 which is helpful in demonstrating functioning thyroid 
tissue. 
6. ANTITHYROID ANTIBODIES(53) 
 This test is useful in demonstrating autoimmune thyroid disorders 
like Hashimoto’s thyroiditis. 
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SUB CLINICAL HYPOTHYROIDISM(44) 
 It is a condition in which thyroid stimulating hormone  is elevated 
with normal serum free thyroxine and triodo thyronine  levels. 
Age – elderly  age group 
Prevalence in adults -2-10% 
AETIOLOGY 
1. Autoimmune thyroiditis – Hashimoto’s disease 
2. Radio active iodine treatment for hyperthyroidism, antithyroid 
drugs. 
3. Neck surgery and radiotherapy  
4. Lithium and amiodarone 
CLINICAL FEATURES 
 Few patients present with symptoms of hypothyroidism like dryskin, 
intolerance to cold, constipation and easy fatiguability, coarse hair , goitre, 
hyperlipidemia, hyperhomocysteinemia, bradycardia, coronary artery 
disease. 
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ASSOCIATED DISEASES 
 Cardiovascular is first and foremost associated disease. Elevation of 
serum triglycerides, total cholesterol and low density liproprotein present . 
L-thyroxine treatment  decreases  LDL and total cholesterol levels, 
which proved in some studies. Left ventricular ejection fraction 
improvement is seen in Echocardiogram with L-thyroxine management. 
WHEN TO TREAT 
1. Symptomatic 
2. TSH level more than 10mIu/ml 
AIM OF THE TREATMENT  
 To lower TSH level to 1-3mIu/L 
CONTRAINDICATIONS: 
 Osteoporosis 
COMPLICATIONS 
(a) Hypercholesterolaemia 
(b) Coronary artery disease 
(c) Overt hypothyroidism 
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Risk of progression to overt hypothyroidism if TSH level more  than  
10 IU/ml is 1-20 percent risk/year 
SUBCLINICAL HYPERTHYROIDISM (44) 
DEFINITION 
Thyroid stimulating hormone present below the normal limits in 
undetectable range with normal free serum thyroxine and triiodo thyronine 
levels. 
ETIOLOGY 
(1)  Partially treated overt hyperthyroidism 
(2)  Early stage Grave’s disease 
(3)  Multinodular goiter 
(4)  Silent thyroiditis 
(5)  Post partum thyroiditis 
CLINICAL FEATURES 
 Non specific symptoms 
(1)  Malaise  
(2)  Nervousness 
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(3)  Anxiety 
Signs 
Tachycardia 
In elderly patients sometimes atrial fibrillation may be  the  first 
manifestation 
PATHOPHYSIOLOGY 
 Pituitary gland sensitiveness to small elevation in serum T3 &  T4 
levels is responsible for this condition 
COMPLICATIONS 
1. Cardiac complications – atrial fibrillation 
2. Osteoporosis 
3. Neuropsychiatric abnormalities 
Progression to overt hyperthyroidism – 1-3 percent 
Antithyroid drugs-methimazole  5mg daily 
    Propylthiouracil 50 to 100mg daily. 
Propylthiouracil mainly used in childbearing age group women. 
Trial of antithyroid drugs for 6 – 12 months tried initially.  
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VARIOUS GUIDELINES 
AACE(American association of clinical Endocrinologists)2002 (43) 
recommends screening for older patients especially women. Mild 
subclinical hypothyroidism if TSH level is 4-10Miu/ml and severe if TSH 
level is >10mIU/ml, treatment regarding subclinical hypothyroidism is 
controversial. Treatment with thyroxine is warranted if mild subclinical 
hypothyroidism symptomatic and severe subclinical hypothyroidism 
follow up annually if TPO ANTIBODIES positive and every 3-5 years in 
negative TPO antibodies. 
ATA( American Thyroid Association) recommends screening for 
both men and women after 35 years and every 5 years. 
ACOG (American college of Obstetrician and Gynecology) 
recommended screening with TSH assay in asymptomatic women over the 
age of 40 years. 
National academy of  clinical biochemistry reference TSH value 
0.4-2.5mIU/ml 
National health and nutrition examination survey screened normal 
population found target TSH value-0.3-2.5 mIU/ml.
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THYROID EVALUATION(47) 
SENSITIVE TSH 
       High             Normal       Low 
 
     FREE T4                       Normal Thyroid                           FREE T4 
 
Low                Normal                   Normal                    High 
 
Hypothyroid      Subclinical hypothyroidism     Free T3           Hyperthyroid
    
      
       Normal          High 
 
     Subclinical hyperthyroidism  
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HYPOTHYROIDISM EVALUATION(45) 
 
 
 TSH and Free T4 
   
    
 
 
 
 
 
 
 
 
 
 
Normal thyroid  
Increased-
permanent 
hypothyroidism 
 
Symptoms and signs 
suggesting hypothyroidism 
TSH  Free T4 low 
or low normal 
TSH Normal or low Free  
T4 (No phenytoin and no 
Salicyclates) 
Primary hypothyroidism  Central hypothyroidism 
TPO  antibody  MRI 
Present 
Hashimoto’s 
disease 
 
Absent    
?Transient 
hypothyroidism 
(post viral 
thyroiditis) 
 
Abnormal 
pituitary or 
hypothalamic 
lesion 
 Normal 
congenital 
TRH 
deficiency, 
Pituitary 
infiltrative 
disease 
Thyroxine  Thyroxine for 4months 
Reduce Thyroxine 
by 50 percent for 6 
weeks 
 Check prolactin and Adrenal glands 
Check TSH 
 
Surgical 
treatment or 
drugs 
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HYPERTHYROIDISM EVALUATION 
 
 
 
  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
TSH, free T4 
Low TSH, High T4 Low TSH, Normal T4 Normal TSH, High T4 
Primary Thyrotoxicosis Free T3 Thyroid Hormone  
resistance syndrome 
Grave ‘s disease 
Yes 
Grave ‘s disease 
No 
Multinodular goiter or 
toxic  adenoma 
Yes No 
Toxic  nodular hyperthyroidism  Low radio nucleide uptake 
Yes No 
Destructive thyroiditis/ Iodine 
excess, excessive thyroxine  
Rule out   other causes stimulates 
chorionic gonadotrophins  
High Normal 
T3 toxicosis Subclinical hyperthyroidism 
Follow up for 6- 12 
weeks 
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ANAEMIA PREVALENT IN THYROID DYSFUNCTION--WHY?(42) 
(1)   Impaired  haemoglobin  synthesis due to deficiency of thyroxine 
(2)   Increased loss of iron with menorrhagia and decreased absorption    
of iron in intestine. 
(3)   Deficiency of folic acid due to decreased intestinal absorption. 
(4)   Pernicious anaemia due to vitamin B12  deficiency 
  Pernicious anaemia is common in autoimmune diseases like chronic 
thyroiditis which is associated with thyroid auto antibodies  formation. 
Other conditions associated with pernicious anaemia are diabetes mellitus 
(islet cell autoantibodies) and  adrenal insufficiency (adrenal 
autoantibodies). 
 
 
 
 
 
 
33 
 
HISTORICAL REVIEW 
1.  Pushpa Bikaha Ram et al (5) studied about impaired thyroid 
function in patients with menstrual disturbances for three months in above 
12 years. Total patients are 40, 82.5% (33) patients had hypothyroidism 
and 17.5% (7) had hyperthyroidism. Conclusion of study is that prevalence 
of menstrual disturbances are menorrhagia (40%), menometorrhagia (10%) 
hypomenorrhoea (15%) secondary amenorrhoea (12.5%) 
2.  Krassas et al(25) studied about menstrual disturbances in 
hypothyroidism patients.  Totally 171 hypothyroid patients included in the 
study. 26.9% (46) patients had subclinical hypothyroidism, 24.6%(42) had 
mild hypothyroidism 48.5%(83) had severe hypothyroidism 88.9% (88) 
patients were thyroid antibodies positive. 21.6%patients were positive for 
thyroid antibodies had menstrual irregularities. The conclusion of this 
study is hypothyroidism  in women is less frequently associated with 
menstrual disturbances. In comparison with mild hypothyroidism, 
menstrual irregularities are more common in severe hypothyroidism.  
Oligomenorrhoea and menorrhagia are the most common menstrual 
disturbances. 
3. Krasas et al(32) conducted study about menstrual disturbances 
in thyrotoxicosis patients. 214 patients are included in the study. 78.5% 
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(168)  patients were present with regular menstrual cycles and 21.5% (46) 
with irregular cycles. He concluded that T4 level changes were higher in 
menstrual disturbances patients, no significant changes in T3 levels and 
Hyperthyroidism  has  less association with menstrual abnormalities. 
4. Koutras(28) studied menstrual disturbances in thyroid disease 
in 214 patients and 21.5% had menstrual disturbances. Polymenorrhoea 
prevalent in hypothyroidism were identified. 
5. Kakuno et al(4) conducted study in Japan in 2010 about 
Thyroid dysfunction. 586 patients were included in the study. Final 
conclusion of this study is 34.8% of severe hypothyroidism  patients had 
menstrual disturbances, mild or moderate hyperthyroidism patient had 
2.5% secondary amenorrhoea and 3.7% hypomenorrhoea . 
6. Wilansky et al 1989(34) studied regarding association of 
menorrhagia with hypothyroidism by thyrotrophin releasing hormone in 67 
patients. 21.73% (15)patients revealed mild primary hypothyroidism had 
good response to thyroxine treatment and symptoms subsided within 3-6 
months. 
7. Solomon et  al(19) studied for 14yrs in reproductive age group 
(20-35yrs) and found that menstrual cycle irregularities is a predisposing 
factor for cardiovascular disease. 
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8. Tamasi et al(29) studied about pulsatile gonadotrophin 
secretion in hypothyroid women of reproductive age in 1997 and found 
that elevated baseline levels with pulsatile gonodotrophin secretion and  . 
gonodotrophin had decreased biological potency and mild ovarian 
resistance. 
9. Borna et al 2002(20) studied 325 thyroid patients and found 
significant association of menstrual irregularities with thyroid patients. 
44.2% patients with hyperthyroidism had oligomenorrhoea  and 
hypothyroid patients had polymenorrhoea, oligomenorrhoea, and 
menorrhagia. 
10. Kaur(3) studied about 100 patients regarding thyroid 
dysfunction in dysfunctional uterine bleeding. 14 patients are hypothyroid 
and one patient is hyperthyroid. Menorrhagia presented in 64.3% patients 
21.4% with oligomenorrhoea and hypothyroidism  is found to have 
menorrhagia. TSH levels less than 13.5 mIU/ml  is either presented  with 
menorrhagia or metorrhagia and value above 20 mIU/ml  is presented with 
oligomenorrhoea. 64.3% hypothyroid patients had proliferative, 21.4% had 
endometrial hyperplasia and remaining 14.3% had secretory endometrium. 
11. Sood(1) studied 394  infertile  women in 2012 for prevalence 
of hypothyroidism and evaluation of response of treatment for 
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hypothyroidism  on infertility. Study detected 23.9% hypothyroidism 
patient.  76.6% infertile women conceived with in short period of time( six 
month to one year). After treatment with thyroxine 25-100µgm improved 
fertility outcome, reduces more expensive tests and invasive procedures in 
those patients.   
12. Lazarus(21) studied about thyroid dysfunction and postpartum 
thyroiditis. The conclusion  of study is the incidence of Postpartum thyroid 
disease occurs in 5-9 percent. Postpartum thyroid dysfunction occurs in 
50%patients with thyroid peroxidase antibody positive.Hypothyroidism 
occurs significantly in transient postpartum thyroid dysfunction. 
13.  Surks et al(17) studied regarding subclinical thyroid for seven 
years and reviewed about 195 papers and concluded that subclinical 
thyroid disease with symptom association are few and recommend against 
routine treatment. TSH level ranges from (S TSH 0.1 – 0.4mIU/l. or  4.5-
10 mIU/l. 
14. Beckmann and haberette(6) studied 337 women suffering from 
polycystic ovarian syndrome and concluded that TSH value more than 2 
mIU/l were younger, had higher body mass index and insulin resistant than 
women with TSH less than 2mIU/l  
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15. Knudsen et al(13) studied 4082 patients about small difference 
in thyroid function and body mass index. This study show that positive 
association between body mass index and TSH level, negative association 
between BMI and  serum T4 and no association between serum T3 levels 
and BMI. This study concluded that slightly increased TSH levels had 
good association with obesity. 
16. Prentice(23) studied retrospective analysis of 50 myxedema 
patients in 2000 and found that 56% had menstrual disturbances. The most 
common abnormality of menstrual disturbance is menorrhagia about 36%. 
Routine thyroid function are of no help in menorrhagia.  Evaluation and 
TRH should be tested for unexplained menorrhagia is the final conclusion. 
17. Zella Ziegler(37) reported two hypothyroid cases on 
methyldopa and platelet function were evaluated. Comparative study were 
done with seven patients of hypothyroidism, not on drugs. BT were higher 
in patients taking methyldopa (33. Min and 26 minutes) and platelet 
aggregation response to epinephrine, collagen and ristocetin were 
abnormal. Platelet aggregation response and bleeding time came back to 
normal limits with thyroxine treatment. Factor VIII  and VIII ristocetin 
cofactor activity were normal. This study finally concluded that 
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methyldopa in hypothyroidism potentiates the platelet  function defects 
mildly. 
18. Zella Ziegler(35) studied 12 hypothyroid patients with aspirin 
challenge and concluded that TSH levels more than 60 IU/ml, had elevated 
hoemostatic activity to aspirin, which is measured by bleeding time. 
Thrombin induced platelet serotonin release were below normal after 
aspirin ingestion. factor VIII and von willebrand factor complex are 
normal. 
19. E.K.Akande studied about the plasma concentration of 
Gonadotrophins, oestrogen and progesterone in hypothyroid females for 
10-14 days consecutively. FSH/LH ratio higher in hypothyroidism in both 
phases of menstrual cycles,  hormone levels were low in this study and 
finally concluded that change in ratio of FSH/LH lead to ovulation failure. 
20. Abdel hamid attia et al(11) made comparative study about 
subclinical hyperthyroidism as potential factor for dysfunctional uterine 
bleeding.  40 euthyroid menorrhagia patients and 20 women having normal 
cycles were included in the study. This study had significant difference 
between study and control group in levels of serum TSH, free T3 and T4. 
prolactin significantly increased in menorrhagia group. 
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21. Raber et al(18) studied 1003 patients about the influence of 
serum prolactin in patients with subclinical and overt hypothyroidism and 
thyroxine treated with hyperprolactinemic patients to differentiate between 
hypothyroidism impaction of confounding drugs and menstrual 
irregularities. Results of this study are menstrual irregularities are not 
common in hyperprolactinemia than in normo prolactinemic women. 
Antipsychotic drugs causes hyperprolactinemia but not antidepressants. 
Thyroxine therapy decreases prolactin levels but menstrual irregularities 
failed to rectify. Final conclusion of this study are menstrual disturbance 
do not have relation with  high prolactin levels in hypothyroidism. 
22. Croatian article 1999(26) published about anaemia in 
hypothyroidism. Anaemia may be the first sign of hypothyroidism and 20-
60% are anaemic in hypothyroidism. Anaemias of uncertain etiology may 
be hypothyroid. Pernicious anaemia  is 20 times more common in 
hypothyroidism. Normocytic anaemia occurs due to thyroid hormone 
deficiency due to an adaptation to a decreased basal metabolism. Thyroid 
hormones directly stimulate growth of erythroid colonies and indirectly 
through erythropoietin. 
23. Sheldon S.Stoffer 1982(56) revealed case reports about 
menstrual disturbances and minimal thyroid insufficiency relationship and 
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levothyroxine response to menstrual irregularity. After levothyroxine 
therapy discontinuation, menstrual disturbances returned in two cases.  The 
responsible mechanism for menstrual dysfunction with minimal thyroid 
insufficiency is not clear. 
24. I Ross Mc dougall 1992(31) gave the clinical impression that 
hypothyroid patients have bleeding tendency, mechanism for bleeding 
diathesis is not known. low concenteration of factor VIII and coagulation 
inhibitors may be responsible for bleeding tendency. Treatment with 
thyroxine helps to overcome this problem. 
25.  Dipak Lahiri and Das Gupta(30) studied 189 hypothyroid 
females about the menstrual pattern and fertility status. 71.09% had 
subclinical hypothyroidism, 46.87% had normal menstrual cycles. 
Oligomenorrhoea was the common abnormality in early age group and 
menorrhagia common in later age group as per this study, more  
subclinical cases are prevalent, so it is necessary to evaluate thyroid 
function in women with menstrual disorders, infertility and recurrent 
pregnancy loss. 
26. American family physician 2004(15) says that after excluding 
pregnancy and iatrogenic cause.  Patient must undergo evaluation to rule 
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out thyroid disease 23.4% hypothyroidism associated with menstrual 
irregularities and 21.5% hyperthyroidism also associated. 
27.  Re-examining treatment for mild hypothyroidism in 2008 (7) 
and prevalence of subclinical hypothyroidism in aging population  is more 
than 10% . Euthyroid  TSH level 0.45-4.5 mIU/L, subclinical 
hypothyroidism TSH level is 4.5-9.9mIU/L and subclinical 
hyperthyroidism TSH level is 0.10-0.45 mIU/L. American college of 
cardiology says that if TSH level more than 10mIU/L they will   have  two 
fold increased risk of heart failure. 
28.  Study regarding levothyroxine replacement on non-high 
density lipoprotein cholesterol in hypothyroid patients in 2007 in journal 
of clinical endocrinology(10) Increased levels LDL-C consistently 
associated with increased risk of development of cardiovascular  diseases. 
Non HDL is better tool for risk assessment. Thyroxine replacement 
therapy induces reduction of non HDL-C levels, a novel atherogenic 
indicator in both subclinical and overt hypothyroidism. 
29. Study regarding association between blood pressure and 
serum TSH  in journal of clinical Endocrinology,2007(12). Thyroid 
dysfunction increases the cardio vascular disease risk. There is an 
increased risk of hypertension in both hypothyroidism and 
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hyperthyroidism. Hypertension related to hypothyroidism reversed after 
thyroxine treatment . Mechanism responsible for hypertension is increased 
systemic vascular resistance and decreased arterial stiffness. There is 
positive and linear association between systolic, diastolic blood pressure 
and TSH and strong to influence  the future risk of cardiovascular disease. 
30. Neelu Sharma(2) studied about thyroid profile in menstrual 
disorders patients. He made a comparative study of group A- thyroid 
profile in menstrual irregularities patients (50) and group B- thyroid 
dysfunction patients (50) for menstrual disturbances.The conclusion of this 
study is 22% hypothyroidism , 14% hyperthyroidism in group A and 56% 
hypothyroid patients ,62% hyperthyroid patients in group B had menstrual 
cycle disturbances. 
 
 
 
METHODOLOGY 
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MATERIALS AND METHODS 
Type of Study:- Open label, randomised Prospective Trial 
  Period of study:- July 2011 to October 2012 
                Sample size -110 
                   Proportion (n) =Z21-Į  P(1-P) /d 2 
    P – estimated proportion 
                                d- desired   precision 
              n =( 1.96)2  0.07 (0.93)/ 0.05× 0.05 
                =3.8416× 0.0651/0.0025 
      =100.05 
                     Place of study  :- Department of Obstetrics and  
    Gynaecology, Govt  Kilpauk Medical        
              College Hospital, Chennai. 
 
Ethical committee clearance obtained on February 2011. 
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SELECTION OF STUDY POPULATION 
The study comprised of 110 abnormal uterine bleeding cases 
admitted in the gynaecology ward through OPD. 
The Study group included women with following complaints. 
1) Oligomenorrhoea 
2) Hypomenorrhoea 
3) Menorrhagia 
4) Polymenorrhoea 
5) Amenorrhoea 
INCLUSION CRITERIA 
1) Age group 18-45 years 
2) Women with any of  the following  menstrual disturbances-
menorrhagia, Oligomenorrhoea, Hypomenorrhoea, 
Polymenorrhoea, Amenorrhoea  with no pelvic pathology. 
3) Non  IUCD user 
4) Not using any hormonal preparations 
5) With symptoms of thyroid dysfunction 
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EXCLUSION CRITERIA 
1) Presence of palpable pelvic pathology – Fibroids, polyp, cervical 
growth 
2) History of Bleeding diathesis and clotting abnormalities 
3) Patient on drug like aspirin, heparin, antithyroid agents and 
thyroxine. 
4) Known case of diabetes mellitus and systemic hypertension 
METHDOLOGY 
 The patients  selected for the study were counselled for undertaking  
the  thyroid function test. Detailed menstrual history including length of 
the cycle, duration of  the flow and number of pads usage were elicited and 
history regarding symptoms of hypothyroidism and hyperthyroidism also 
elicited. General examination including anaemia, height of the patients  
(cm), weight of the patient (kg), thyroid enlargement were assessed. 
 Body mass index was calculated using height and weight. Systemic 
examination were carried out.  Abdominal examination, speculum and 
pelvic examination done to rule out other causes of abnormal uterine 
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bleeding. Investigations-complete blood count, platelet count, bleeding 
time, and clotting time, urine routine, blood sugar, RFT carried out. USG 
Pelvis  done. Histopathological examination of endometrium  performed 
by pipelle’s curette. 
 Thyroid function test-Serum TSH, free T3 and free T4  are 
compulsory.  5ml of blood was taken in dry glass contains without any 
anticoagulant. Fasting sample was taken, TSH assay was performed using 
IRMA Kit (Immuno radio metric assay) 
PHYSIOLOGICAL RANGE 
 TSH-0.5 to 5 m IU/ml  
 RESULTS AND ANALYSIS  
 
47 
 
 
RESULTS OF THE STUDY 
Patients with thyroid dysfunction were grouped as thyoid 
dysfunction cohort and the remaining   patients had AUB alone  were 
grouped as normal cohort. 
The following factors were taken for analysis- age , parity ,AUB 
types, socioeconomic status,episodes of AUB, body mass index, family 
history of thyroid disorders,uterine size,  endometrial histopathology 
,haemoglobin, bleeding time,clotting time and platelet count. The predictor 
of thyroid dysfunction was analysed using the factor duration of AUB and 
regression coefficient curve.Logistic  regression model analysis is used to 
find  out the effective predictor of  thyroid dysfunction. 
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Table 1: 
AGE & THYROID DYSFUNCTION DISTRIBUTION 
 
AGE 
(Years) 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
18-24 25 25.3 2 18.2 
25-35 48 48.5 7 63.6 
36-45 26 26.3 2 18.2 
 
Chi-square  = 0.91   p = 0.6 not significant 
Among 110 patients,48 (48.5%)  belongs  to normal  cohort  and 7 
(6.3%) belongs to thyroid dysfunction group in age group 25-35 years . 
Out  of  11 thyroid dysfunction ,majority  7 (63.6%) were in age group of  
25-35 years. 
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There  is no significant difference  between  thyroid dysfunction and 
non thyroid dysfunction with respect to age group. 
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Table 2:  
PARITY & THYROID DYSFUNCTION DISTRIBUTION 
 
PARITY 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
NulliParous 4 4 1 9.1 
P1L1 9 9.1 1 9.1 
P2L2 54 54.5 6 54.5 
P3L3 25 25.3 2 18.2 
P4L4 7 7.1 1 9.1 
 
Chi-Square  =  0.813   P =  0.6 not significant 
Multiparous (P2L2)54.5% in the normal cohort and 54.5% in the thyroid 
dysfunction cohort. No statistical significance between thyroid and non 
thyroid samples with respect to parity. 
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Table 3 : 
AUB & THYROID DYSFUNCTION DISTRIBUTION 
 
AUB TYPES 
 
NORMAL COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
 
Menorrhagia 
 
39 
 
 
39.4 
 
7 
 
63.6 
 
Oligomenorrhoea 
 
28 
 
28.3 
 
0 
 
0 
 
Amenorrhoea 
 
16 
 
16.2 
 
1 
 
9.1 
 
Hypomenorrhoea 
 
4 
 
4 
 
1 
 
9.1 
 
Polymenorrhoea 
 
5 
 
5.1 
 
0 
 
0 
 
Menometorrhagia  
 
 
7 
 
7.1 
 
2 
 
 
18.2 
 
Menorrhagia  presents in 39.4% patients in normal cohort and 
63.6% in thyroid dysfunction cohort.  Hypomenorrhoea  presents in 4% 
normal cohort and 9.1% thyroid dysfunction cohort. 
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Out of 110 patients, menorrhagia in 41.81%, oligomenorrhoea in 25.45%, 
amenorrhoea  in 15.45%, hypomenorrhoea in 4.54%, polymenorrhoea in 
4.54%  and metorrhagia in 8.18% of the AUB population. 
 
 
 
 
 
53 
 
 
 
  Hypothyroidism  presents in 7.27%, subclinical hypothyroidism in 
1.81% and hyperthyroidism  in 0.92% patients. 
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Table 4 : 
MENORRHAGIA & THYROID DYSFUNCTION DISTRIBUTION 
 
AUB 
 
NORMAL 
COHORT 
 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Menorrhagia 39 39.4 9 81.8 
Others 60 60.6 2 18.2 
  
Chi-square-0.008               p-0.01   significant 
 Menorrhagia  in 39.4% patients in normal cohort and 81.8% patients  
in thyroid dysfunction cohort.  
There exist a definite significance  between menorrhagia  and 
thyroid dysfunction  patients. 
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Table 5 : 
OLIGOMENORRHOEA & THYROID DYSFUNCTION 
DISTRIBUTION 
 
 
AUB 
 
NORMAL 
COHORT 
 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Oligomenorrhoea 28 28.3 2 18.2 
Others 71 71.7 9 81.8 
 
 
Chi-Square -0.377   P =  0.75  not significant 
Oligomenorrhoea  presents in 28.3% patients in normal cohort and 
18.2% patients in thyroid dysfunction cohort. No statistical significance 
between Oligomenorrhoea and thyroid dysfunction. 
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Table 6 : 
AMENORRHOEA & THYROID DYSFUNCTION 
 
 
AUB 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Amenorrhoea 16 16.2 1 9.1 
Others 83 83.8 10 90.9 
 
Chisquare-0.465                           p-0.9303  not significant 
Amenrrhoea  presents in 16.2% patients of normal cohort and 9.1% 
patients of thyroid dysfunction cohort. No statistical significance between 
amenorrhoea and thyroid dysfunction. 
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Table 7 : 
HYPOMENORRHOEA & THYROID DYSFUNCTION 
DISTRIBUTION  
 
 
AUB 
 
NORMAL 
COHORT 
 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Hypomenorrhoea 4 4 1 9.1 
Others 95 
 
96 10 90.9 
 
Chi-Square -0.415   P =  0.8 not significant 
Hypomenorrhoea presents in 4% of normal cohort and 9.1% in 
thyroid dysfunction cohort. No statistical significance between 
hypomenorrhoea and thyroid dysfunction. 
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Table 8 : 
POLYMENORRHOEA & THYROID DYSFUNCTION 
DISTRIBUTION  
 
AUB 
 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Polymenorrhoea 5 5.1 0 0 
Others 94 94.9 11 100 
 
Chi-Square -0.5844  P = 0.99 not significant 
Polymenorrhoea presents in 5.1% in normal cohort and no patients 
in thyroid dysfunction cohort. No stastitical significance exists between 
thyroid dysfunction and polymenorrhoea. 
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Table 9 : 
EPISODES OF AUB IN STUDY POPULATION 
 
 
EPISODES OF 
AUB 
 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
First 83 83.8 8 72.7 
Second 160 16.2 3 27.3 
 
Chi-Square -0.855   P =  0.3  not significant 
Majority of the patients came to  hospital in the first episode -83.8% in 
normal cohort and 75.7% in thyroid dysfunction cohort. 
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No statistical significance between thyroid and non thyroid samples 
with respect to Episodes of AUB 
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Table 10: 
SOCIOECONOMIC STATUS & THYROID DYSFUNCTION 
DISTRIBUTION 
 
SOCIOECONOMIC 
STATUS & 
THYROID 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Upper Middle 14 14.1 1 9.1 
Lower Middle  42 42.4 3 27.3 
Upper Lower  43 43.4 7 63.6 
 
 
Chi-Square = 1.6    P =0.4    Not significant 
Majority of  AUB patients 43.4%  in normal cohort  and 63.6% in 
thyroid dysfunction  cohort  belongs  to upperlower socioeconomic class. 
No statistical  significance exists between socioeconomic status and 
thyroid dysfunction. 
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Table 11 : 
FAMILY HISTORY AND THYROID DYSFUNCTION 
DISTRIBUTION 
 
 
Family 
History  
 
NORMAL COHORT 
 
THYROID 
DYSFUNCTION COHORT 
No of cases % No of cases % 
Present  3 3.01 2 18.1 
Absent  96 96.99 9 81.9 
 
18.1% thyroid dysfunction had positive association with family 
history of thyroid disorders. 3% of normal cohort had association with 
family history of thyroid disorders. 
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Table 12 : 
UTERINE SIZE & THYROID DYSFUCTION DISTRIBUTION 
(USG) 
 
 
UTERINE SIZE  & 
THYROID 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No of cases % No of cases % 
Normal 67 67.7 3 63.6 
Bulky 32 32.3 8 36.4 
 
Chi-Square = 6.98    P =0.08  not significant 
32.3%  in normal cohort  and 36.4%  in thyroid dysfunction cohort 
had bulky uterus. No stastitical association exists between thyroid 
dysfunction and uterine size. 
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Table 13 : 
BMI & THYROID DYSFUNCTION 
 
 
 
 
 
NO.OF 
CASES 
 
MEAN 
BMI 
 
STANDARD 
DEVIATION 
 
STANDARD 
ERROR OF 
MEAN 
 
Normal 
Cohort 
 
 
 
99 
 
22.51 
 
1.71 
 
0.172 
 
Thyroid 
Dysfunction 
Cohort 
 
 
11 
 
26.95 
 
2.891 
 
0.872 
 
P= 0.000<0.001  SIGNIFICANT.  
Majority of thyroid dysfunction patients are in upper limit of over 
weight. 
There exists a definite significance between thyroid dysfunction and 
body mass index. 
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Table 14 : 
HPE OF ENDOMETRIUM DISTRIBUTION IN AUB 
POPULATION 
HPE 
NORMAL COHORT 
THYROID 
DYSFUNCTION COHORT 
No Percent No Percent 
Anovulatory 10 10.1 2 18.2 
Atrophic 1 1 0 0 
Adenomatous 
hyperplasia 2 2 0 0 
Cystic  
hyperplasia 2 2 0 0 
Simple  
hyperplasia 2 2 0 0 
Secretory 24 24.2 2 18.2 
Proliferative 49 49.5 6 54.5 
Ovulatory 2 2 0 0 
Stromal decidual 
asynchronisation 7 7.1 1 9.1 
 
Chi-square-1.8       pvalue-0.98 Not  significant 
In  histopathological examination of endometrium  49.5% in normal 
cohort and 54.5% thyroid dysfunction cohort  reported as proliferative  
endometrium. 
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HPE OF ENDOMETRIUM DISTRIBUTION IN AUB 
POPULATION 
 
No stastitical association exists between  endometrial HPE and  
thyroid dysfunction. 
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Table 15 : 
HPE ENDOMETRIUM AND THYROID DYSFUNCTION 
DISTRIBUTION 
HPE 
NORMAL 
COHORT 
HYPER 
THYROIDISM 
HYPO 
THYROIDISM 
SUBCLINICL 
HYPO 
THYROIDIM 
No. Percent No. Percent No. Percent No. Percent 
Anovulatory 10 10.1 0 0 1 12.5 1 50 
Atrophic 1 1 0 0 0 0 0 0 
Adenomatous 
hyperplasia 2 2 0 0 0 0 0 0 
Cystic  
hyperplasia 2 2 0 0 0 0 0 0 
Simple  
hyperplasia 2 2 0 0 0 0 0 0 
Secretory 24 24.2 1 100 1 12.5 0 0 
Proliferative 49 49.5 0 0 5 62.5 1 50 
Ovulatory 2 2 0 0 0 0 0 0 
Stromal 
decidual 
asynchronisation 
7 7.1 0 0 1 12.5 0 0 
 
Chi-square – 8.643   p value – 0.9   not significant 
Majority of endometrial HPE came as proliferative endometrium in 
thyroid dysfunction  and no endometrial hyperplasia in thyroid dysfunction 
cohort. No statistical significance exists between particular type of HPE 
and thyroid dysfunction. 
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Table 16 : 
CLINICAL THYROID ENLARGEMENT DISTRIBUTION IN AUB 
THYROID 
ENLARGEMENT 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
COHORT 
No. Percent No. Percent 
Not enlarged 97 98 6 54.5 
Thyroid enlarged 2 2 5 45.5 
 
Chisquare – 31.3   p value – 0.000 Significant 
 
There exists a significant statistical association between clinical 
thyroid enlargement and thyroid dysfunction.  
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Table 17 : 
SYMPTOMS OF THYROID DISEASE DISTRIBUTION IN AUB 
POPULATION 
SYMPTOMS 
NORMAL 
COHORT 
THYROID 
DYSFUNCTION 
No. Percent No. Percent 
Absent 98 99 7 63.6 
Present 1 1 4 36.4 
   
Chi-square – 28.5   p value – 0.000 significant. 
99
1
63.6
36.4
0
20
40
60
80
100
120
Symptoms Absent Symptoms present
Normal cohort
Thyroid dysfuntion
 
There exists a stastitical significance between symptoms of thyroid disease 
and thyroid dysfunction . 
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Table 18 : 
BLEEDING TIME IN AUB POPULATION 
THYROID 
DYSFUNCTION 
NUMBER 
MEAN 
(Secs) 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF 
MEAN 
Absent 99 118.22 34.15 3.43 
Present 11 106.36 43.36 13.075 
 
P>0.05. Not significant.  Though  the  Mean bleeding time in  
Thyroid dysfunction is  decreased than the normal cohort, no statistical 
significance exists.  
 
 
 
 
 
71 
 
 
Table 19 : 
CLOTTING TIME IN AUB POPULATION 
THYROID 
DYSFUNCTION 
NUMBER 
MEAN 
(Secs) 
STANDARD 
DEVIATION 
STANDARD 
ERROR MEAN 
Absent 99 375.53 106.44 10.69 
Present 11 398.64 72.80 21.95 
 
P value  -0.485   
Mean clotting time in thyroid dysfunction patients – 398.64 secs. 
Mean clotting time in normal cohort (AUB patients – 375.53 secs) 
Mean clotting time in  thyroid dysfunction cohort  increased than 
normal cohort. 
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Table 20: 
PLATELET DISTRIBUTION IN AUB POPULATION 
THYROID 
DYSFUNCTION 
NUMBER 
MEAN 
(Lakhs) 
STANDARD 
DEVIATION 
STANDARD 
ERROR MEAN 
Absent 99 2.25 0.75 0.07 
Present 11 2.29 0.78 0.235 
 p value  -0.88 
No difference found between platelet count in both groups. Mean 
platelet count is around 2.2 lakhs in both groups. 
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Table 21: 
HAEMOGLOBIN IN AUB POPULATION 
THYROID 
DYSFUNCTION 
NUMBER MEAN 
STANDARD 
DEVIATION 
STANDARD 
ERROR 
MEAN 
Absent 99 8.99 0.370 0.112 
Present 11 9.05 0.679 0.068 
 
Mean hemoglobin level in normal cohort -8.9gm%  
Mean hemoglobin level in thyroid dysfunction cohort-9gm% 
No difference found between in both groups. 
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Table 22 : 
DURATION OF AUB IN THE STUDY POPULATION 
THYROID 
DYSFUNCTION 
NUMBER MEAN 
STANDARD 
DEVIATION 
STANDARD 
ERROR MEAN 
Absent 99 5.5 3.340 0.336 
Present 11 7.7 5.5 1.668 
                                                                                   P value  -0.06 
Mean duration of AUB in thyroid dysfunction group-7.7 months. 
Mean duration of AUB in normal cohort-5.5 months. 
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DURATION OF AUB- ROC CURVE 
We have done  the ROC  curve, for  Duration of  AUB with respect 
to thyroid dysfunction. The  following  ROC  curve  indicates  sensitivity 
is high , but  specificity is low. The  curve gives cut off criterion as  >4.  
DURATION
0 20 40 60 80 100
0
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80
100
100-Specificity
S
en
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ity
 Sensitivity: 90.9
 Specificity: 39.4
 Criterion : >4
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Table 23 : 
BINARY LOGISTIC REGRESSION ANALYSIS 
VARIABLES Wald Sig. Exp(B) 
Menorrhagia 4.064 0.044 11.596 
Thyroid enlargement 10.050 0.002 87.104 
Symptoms 6.689 0.010 58.566 
 
Menorrhagia ,thyroid enlargement and symptoms overall predict 
93.6% thyroid dysfunction patients. menorrhagia alone can predict 11.5% 
thyroid dysfunction patient 
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Table 24 : 
THYROID DYSFUNCTION DISTRIBUTION AS PER INDIAN AND  
AACE( REFERENCES) 
COHORT 
INDIAN AACE 
NO. PERCENT NO. PERCENT 
Normal 99 90 86 78.2 
Thyroid dysfunction 11 10 24 21.8 
 
As per Indian standard, thyroid dysfunction association with 
abnormal uterine bleeding is 10%. According to AACE guidelines 
abnormal uterine bleeding associated with thyroid dysfunction is 21.8% in 
this study. 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
 The study was conducted in the Department of Obstetrics and 
Gynecology, Kilpauk Medical College Chennai. It comprises of 110 
abnormal uterine bleeding patients. 
 The study group includes abnormal uterine bleeding after excluding 
local pathology and systemic disease like diabetes mellitus, hypertension 
and known case of thyroid disorder. 
 The most common age group studied was between 25-35 years 
(55.5%).The present study concludes that there is no significant 
association between thyroid disorders with respect to age group. Majority 
of thyroid dysfunction (63.6%) were in the age group  of  25-35 years. 
 Multiparous women (P2L2) constitute the major part of this study 
(54.5%) Most of the women affected by thyroid dysfunction were also 
multiparous (P2L2). Even though nulliparous women presents earlier to 
gynecology OPD for infertility evaluation, thyroid dysfunction is noted in 
9.1% population  in that age group. 
 The most common type of AUB presentation in this study is 
menorrhagia (43.6%). In thyroid dysfunction, menorrhagia constitutes the 
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highest abnormality (63.6%) and least is polymenorrhoea in both groups, 
AUB patients alone (5.1%) and thyroid dysfunction  
COMPARISON  OF MENORRHAGIA –PRESENT TRIAL Vs  
REFERENCES 
STUDY AUB PERCENTAGE 
Prentice (23)   Menorrhagia  36% 
Kaur (3) Menorrhagia 64.3% 
Puspha Bikha Rom et al(5) Menorrhagia 40% 
Wil kansky (34) Menorrhagia 22% 
Present trial Menorrhagia 43.6% 
 
 This study was against the study of Koutras(28) which revealed 
polymenorrhoea prevalence high in hypothyroidism. 
 Thyroid dysfunction is absent in oligomenorrhoea  and 
polymenorrhoea . Next to menorrhagia, metorrhagia constitutes about 
18.2% in the  thyroid dysfunction group. 
 There exists no significant association  between the episodes of 
AUB and thyroid dysfunction. Even though majority of women attended 
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Gynecology OPD in first episode in normal cohort is 83.8% and thyroid 
dysfunction cohort is 72.%. 
 Majority of women belongs to socio economic class upper lower, 
43.4 % in normal cohort and 63.6%thyroid dysfunction cohort. No 
significant association is found between thyroid dysfunction and socio 
economic status. 
            Family history of  thyroid disorders is present in 18.1%  of thyroid 
dysfunction. 
 Bulky uterus  is present in 32.3% normal cohort and 36.4% in 
thyroid dysfunction cohort.  A significant association seen between the 
uterine size and thyroid dysfunction. 
 BMI in thyroid dysfunction group are in the upper limit of   over 
weight group  (mean BMI – 26.95) and normal BMI (mean BMI – 22.5) in 
normal cohort BMI,  BMI and thyroid dysfunction have  got significant 
association. 
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COMPARISON OF BMI-PRESENT TRIAL Vs REFERENCES 
STUDY BMI AND TSH 
Knudsen et al (13) Positive association 
Beckmann and Haberette (6) Positive association 
Present study Positive association 
 
Most common endometrial HPE  is proliferative in normal cohort 
(49.5 %)  and in thyroid dysfunction cohort (54.5%)  Endometrial 
hyperplasia absent in thyroid dysfunction cohort. 
COMPARISON OF  ENDOMETRIAL HISTOPATHOLOGY  IN 
THYROID DISORDERS –PRESENT TRIAL Vs REFERENCES 
STUDY THYROID DISORDERS ENDOMETRIUM HPE 
Kaur (3) Hypothyroidism 
Proliferative - 64.3% 
 
Endometrial  
Hyperplasia - 21.4% 
 
Secretory    - 14.3 
 
Neelu Sharma (2) Hypothyroidism 
Proliferative - 36.36% 
 
Secretory      - 21.4% 
 
Stromal Glandular 
Asynchronisation - 27.27% 
Present study Hypothyroidism 
Proliferative – 62.5% 
 
Secretory      - 12.5% 
 
Anovulatory – 12.5% 
 
Stormal Glandular 
Asynchronisation – 12.5% 
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Thyroid enlargement is present in 45.5% normal cohort and 
symptoms of thyroid disease in normal cohort is 1% and 36.4% of thyroid 
dysfunction cohort. Thyroid enlargement and symptoms of thyroid disease 
have  got significant association with thyroid dysfunction. 
In coagulation profile, mean bleeding time in thyroid dysfunction is 
decreased than normal cohort and mean clotting time in thyroid 
dysfunction is increased than in the  normal cohort.  Mean platelet count in 
both groups  are around 2.2 lakhs and within normal limits. 
Mean haemoglobin level in both groups are 9 gm%. 
Mean duration of AUB in thyroid dysfunction is 7.7 months and in 
normal cohort is 5.5 months.  Majority of AUB population presented to the 
gynecology OPD in  the first episode  83.8% of the cases. Depending on 
the duration of AUB, regression  coefficient curve is used in this study to 
predict thyroid dysfunction.  This test has high sensitivity (90.9%) than 
specificity (39.4%). 
Menorrhagia, symptoms of thyroid disease and thyroid enlargement 
are the three variables used to predict 93.6% thyroid dysfunction. 
Menorrhagia alone can predict 11.5% thyroid dysfunction. 
 
SUMMARY 
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SUMMARY 
The study population includes 110 abnormal uterine bleeding patients. 
1. The most common age group studied were between 25-35 years is 
48.5% in normal cohort and 63.6% in thyroid dysfunction cohort. 
2. Multiparous (P2L2) were the majority, 54.5% in both groups.  
Nulliparous 4% in normal cohort and 9.1% in thyroid dysfunction 
cohort.  
3. The most common type of AUB in both groups are menorrhagia. 
(39.4% Vs 63.6%) Menorrhagia got significant association with 
thyroid dysfunction. 
4. Hypothyroidism presents in 7.27%, subclinical hypothyroidism in 
1.18% and hyperthyroidism in 0.92% of the study population. 
5. Majority of  AUB population attended Gynecology OPD in first 
episode (81.8%) to seek health care at the earliest. 
6. Most common socioeconomic class studied belongs to upper lower 
class (kuppusamy’s scale) which comprises about 43.4% in normal 
cohort and 63.6% in thyroid dysfunction cohort. 
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7. Thyroid dysfunction patients  18.1% had  association with family 
history  of thyroid disorders. 
8. Uterine size and thyroid dysfunction had no significant association 
in this study (32.3% Vs  36.4%)  
9. Obese people are prone for thyroid dysfunction.  In this study 
thyroid dysfunction cohort are in the upper limit of overweight 
group (26.95%) and normal cohort in normal BMI. 
10. Majority of the hypothyroidism patients had proliferative 
endometrium (62.5%) and minority of patients had secretory 
endometrium (12.5%) 
11. Clinically thyroid enlarged patients (45.5%) and those patients who 
got symptoms of thyroid disease (36.4%) are vulnerable for thyroid 
disorders. 
12. Bleeding time and clotting time are within normal limits in both the 
groups. 
13. Platelet count in both groups are within normal limits (2.2lakhs). 
14. Mean haemoglobin level in both groups was 9 gm%. 
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15. Even though majority of patients attended healthcare facility very 
earlier, mean duration of AUB in thyroid dysfunction group is 7.7 
months depending on the duration of AUB. 
16. Menorrhagia, thyroid enlargement and symptoms of thyroid disease 
are the three variables together used to predict thyroid dysfunction 
in 93.6% 
CONCLUSION 
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CONCLUSION 
Our study highlights the following facts: 
The significant association between abnormal uterine bleeding and 
thyroid disorder (10%).  It brings into focus the increased incidence of 
hypothyroidism among women with menorrhagia . 
It  proves beyond doubt that TSH assay can be used in selective 
screening of women with abnormal uterine bleeding and  in  prevalence of 
subclinical hypothyroidism ( 21.4%   ) as per AACE guidelines in this 
study.  We are treating only tip of the disease but the submerging part of 
the disease also needs surveillance at frequent intervals to treat  patients at 
the earliest and prevent morbidities in later life. 
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PROFORMA 
Name                                 Age      Sex         Unit           IP No 
Address                                                         D.O.A 
                                                                      D.O.P 
                                                                      D.O.D 
Chief complaints 
H/o presenting illness 
Bleeding p/v 
Duration 
Quantity-scanty/moderate/excessive 
              Flow last for------------ days 
             H/o passing clots yes/no 
            H/o Dysmenorrhoea 
Menorrhagia   Yes/No 
Oligomenorrhoea   Yes/No 
Amenorrhoea    Yes/No 
Hypomenorrhoea    Yes/No 
Polymenorrhoea      Yes/No 
MENSTRUAL HISTORY: 
Attained menarche------- Years 
Duration of cycles 
Duration of flow 
LMP 
MARITAL HISTORY: 
Married since-------Years 
OBSTETRIC HISTORY: 
Para                   Living               Abortion 
FTNVD /FTLSCS 
Sterilization- Yes/No 
PAST HISTORY: 
Hypertension/diabetes mellitus/tuberculosis/asthma/thyroid disorders 
FAMILY HISTORY OF THYROID DISORDER –Yes/No 
General Examination 
Height           weight         BMI 
Temp            Pulse rate       BP 
Patient 
Anaemic              pedal edema             skin thickening 
CVS                                        RS 
P/A 
Examination of vulva- 
Speculum examination -vagina 
                                       Cervix 
Bimanual pelvic examination 
Cervix 
Uterus- anteverted/retroverted 
Normal size/bulky/small 
Soft/firm/hard 
Mobile/fixed 
Fornices free, Yes/No 
Investigation 
1.Complete blood count-  Haemoglobin 
                   Total  count 
      Differential  count 
2.platelet count 
3.Bleeding time 
4.clotting time 
5.urine routine 
6.blood sugar 
7.renal function test 
Blood urea/serum creatinine 
8.HIV 
9.ultrasonogram pelvis 
10.thyroid function test 
Free t3----- 
Free t4----- 
TSH------- 
11.endometrial sampling- histopathological examination 
 
KEY TO MASTER CHART 
Type   - Type of AUB 
Dur   - Duration of AUB 
EPI   - Episodes of AUB 
SES  - Socioeconomic Status 
FH   - Family History 
BMI   - Body Mass Index 
HB   - Haemoglobin 
UTS  - Uterine Size 
HPE  - Histopathological examination of Endometrium 
BT   - Bleeding Time 
CT   - Clotting Time  
P  - Proliferative endometrium 
S  - Secretory endometrium 
A   - Anovulatory endometrium 
AT   - Atrophic endometrium 
SGA  - Stromal Glandular Asynchro nistation 
Hyper.s - Simple hyperplasia  
Hyper-Ad - Adenomatous hyperplasia  
F H THYROID BT CT
PLATELET 
COUNT
P L A
JEYA KUMARI 35 2 2 0 M 12 2 IV N 23.5 9.2 N N 2.5 1.2 2.6 P 0 68 145 1.6
KALA 40 3 3 0 H 4 1 V N 24.6 10.2 B N 2.9 1.6 1.4 SDA 0 125 320 2.2
MAHALAKSHMI 41 2 2 0 M 6 1 V N 28.2 8.6 B N 3.17 1.39 1.68 P 0 134 260 3.4
VANITHA 24 1 1 0 O 3 1 IV N 25.4 9.4 N N 2.97 1.22 2.18 S 0 142 290 1.6
LAKSHMI PRIYA 26 3 1 1 O 4 1 III N 26.2 10.4 B N 2.58 0.91 4.44 P 0 145 520 1.8
MALAR 45 4 3 0 M 6 2 V N 24.4 8.8 N N 2.76 1.04 5.112 P 0 175 380 2.5
SHANTHI 45 2 4 0 M 6 2 V N 26.4 7.6 N N 2.72 1.38 1.22 P 0 180 410 2.6
LAKSHMI PRIYA 38 2 2 0 M 5 1 IV N 23.6 9 B N 2.18 1.14 1.23 AN 0 120 360 3.5
SARADHA 44 2 2 0 M 4 1 V N 24.2 8.4 N N 2.61 1.24 0.89 P 0 132 270 1.6
SUDALI 38 3 3 0 M 7 2 V N 26.2 8.2 B N 2.78 1.04 1.62 AN 0 140 265 1.8
MAHALAKSHMI 40 2 2 0 O 6 1 V N 29.2 8.8 N N 3.17 1.39 1.68 S 0 150 340 1.4
LOGANAYAGI 38 2 2 1 M 9 1 V N 28.6 7 N N 2.54 1.06 1.977 IS 0 155 280 2.4
SUMATHY 30 2 2 0 O 6 1 IV N 24.6 8.2 B N 2.86 1.02 2.912 S 0 95 310 2.5
ANNAKILI 33 2 2 0 M 8 1 V N 30.4 8.8 B Y(HYPO) 1.87 0.7 6.1 P 1 65 540 2.6
SUSEELA 40 2 2 0 A 6 1 IV N 28.2 8.9 N N 2.68 1 1.44 P 0 120 400 3.3
SENGANI 44 2 2 0 M 2 2 V N 24.8 8.4 N N 3.6 1.1 3.72 hyperplasia simple0 140 410 1.8
PUSHPA 42 2 2 0 O 6 2 V N 25.6 9.4 B N 2.4 1.42 2.8 p 0 185 360 1.6
ANNAPOORANI 40 2 2 1 M 9 1 V N 28.4 8.8 N N 2.8 1.2 2.6 p 0 90 290 1.8
SATHIYA 37 3 3 0 O 6 1 IV N 29.4 9 N N 2.2 1.06 1.46 p 0 100 295 1.2
SAROJA 36 2 2 2 M 5 1 V N 27.6 9.6 B N 2.7 1.2 2.6 AN 0 125 370 1.4
LAKSHMI 38 2 2 1 M 2 1 IV N 26.3 8 B N 2.1 1.14 1.23 P 0 155 310 2.4
VIJI 25 2 2 0 O 6 2 III N 25.8 8.6 B N 3.4 1.2 3.67 S 0 140 340 2.8
NIVEDHA 22 1 1 0 M 4 1 IV N 26.7 9.4 N N 2.4 1.2 1.37 P 0 125 560 3.2
LATHA 37 2 2 3 M 6 1 IV N 29.2 8.2 N N 2.2 1.09 3.16 P 0 102 420 4.1
MUTHULAKSHMI 27 2 2 1 A 7 1 V N 24.3 10.6 N N 2.67 1.16 3.54 SDA 0 95 450 1.8
GOVINDAMMAL 38 3 3 0 A 6 1 IV Y 27.8 9.6 N Y(HYPO) 1.6 0.5 6.6 p 0 120 410 1.6
REVATHY 30 0 0 0 O 5 1 IV N 22 9.8 N N 2.4 1.2 3.2 S 0 185 320 1.2
JULIET 37 2 2 0 M 24 2 V N 24.6 8.8 N N 2.8 1.06 2.2 P 0 126 345 1.4
JEYA KUMARI 28 2 3 0 M 2 1 III N 20.8 9.2 B N 2.6 1.08 4 P 0 120 420 2.4
VISALAKSHMI 27 2 0 0 H 8 1 IV N 26.4 9.4 N Y(SUB) 2.2 1.06 5.8 AN 1 95 360 2.6
NEULAZHI 34 3 2 0 A 6 1 V N 24.8 9.6 N N 4.1 1.42 2 s 0 55 390 3.2
GEETHA 24 0 2 0 O 24 1 III N 24.2 9.5 N N 2.6 1.2 4.8 IS 0 135 620 3.1
AMULU 27 2 4 0 H 12 1 IV N 23.8 9.8 N N 2.2 1.2 3.4 SDA 0 150 480 2.1
ALAMELU 45 2 2 0 M 2 1 IV N 22.7 8.6 N N 2.69 1 1.44 P 0 180 510 1.7
MASTER CHART
FREE T4 TSH HPEEPI SES BMI HB UT S THYROID
PARITY
NAME AGE TYPE DUR FREE T3
JEENATH 42 4 4 2 M 7 1 V N 23.6 9.2 B N 2.7 1.2 3.2 P 0 75 460 2.4
SARATHA 40 3 2 0 A 3 1 IV N 22.8 8.8 N N 2.72 1.4 2.9 0 85 470 3.8
KANAGIMANI 40 2 2 0 M 6 2 V Y 29.4 8.4 B Y(SUB) 1.7 0.76 9.4 P 1 90 445 1.5
JOTHIBAI 39 3 3 0 M 5 1 IV N 24.6 9 N N 2.6 1.4 3.2 AN 0 120 520 1.8
VALLI 45 4 4 1 M 7 1 V N 25.8 8.6 N Y(HYPO) 1.2 0.5 7.2 SDA 0 65 460 2.2
KALIAMMAL 37 3 3 0 M 4 1 V N 27 9.2 N N 2.6 1.4 3.8 P 0 100 490 1.7
VENNILA 42 3 3 0 O 5 1 IV N 26.4 9.4 N N 2.4 1.2 1.8 S 0 75 540 1.6
MALARKODI 45 2 2 2 O 3 1 V N 26.4 9 B N 2.6 1.7 3.2 S 0 120 480 3.4
LAKSHMI 44 3 2 0 M 6 1 V N 22.6 8.2 B N 2.8 1.6 3 hyperplasia simple0 140 510 3.2
REVATHY 42 3 3 0 M 7 1 V N 20.8 9.2 B N 2.7 1.3 2.8 hyperplasia adenomatous1 110 460 1.5
INDIRA 24 0 0 0 O 6 1 III N 26.9 9 N N 2.2 1 1.4 AN 0 125 470 1.6
BHUVANESHWARI 45 2 2 0 M 4 1 III N 24.2 9.6 N N 2.4 1.2 2.4 P 0 140 285 4.1
MEHAR SULTANA 36 3 2 0 O 5 1 V N 23.6 8.8 B N 3.1 1.8 4.16 P 0 110 360 2.7
MALIGA 43 4 5 0 M 6 2 IV N 23.8 7.8 B N 2.8 1.7 3.2 S 0 95 400 1.6
PUSHPA 40 2 2 2 O 3 1 IV Y 25.2 8.4 N N 2.6 1.2 4.2 S 0 85 330 1.4
DHANALAKSHMI 42 4 4 0 P 6 1 V N 26.2 10.2 N N 2.8 1.1 1.6 P 0 110 560 2.4
LATHA 32 2 2 0 M 3 1 V N 24.8 9.8 N N 2.3 0.9 0.8 P 0 75 420 1.3
DEVIKA 45 4 4 0 M 11 1 V N 26.3 8 B N 2.6 1.4 2.45 P 0 150 440 1.4
RENUKA 35 3 3 0 M 2 1 III N 23.9 9.6 N N 2.7 1.6 2.8 P 0 75 390 2.5
MADHAVI 35 3 3 0 M 6 1 III N 25.6 9.2 B Y(HYPO) 1.6 0.4 6.4 P 0 65 310 2.6
KARPAGAM 34 2 2 0 O 3 1 IV N 22.2 8.6 B N 2.9 1.6 2.6 S 0 90 275 2.1
CHINNAPONNU 45 3 3 0 M 4 1 V N 24 8.4 N N 2.4 1.2 3.8 hyperplasia cystic0 120 330 1.4
MAHESHWARI 42 0 0 0 O 24 2 IV N 24.2 9.2 B Y(HYPER) 9.36 4.4 0.04 s 0 180 290 1.3
USHA RANI 40 3 3 0 M 4 1 III N 25.6 8.8 N N 2.4 1.8 3.2 p 0 165 320 1.8
VALLIAMMAL 42 2 2 0 M 6 1 V N 23.2 9.2 N N 2.8 1.6 3.6 p 0 65 550 1.6
RAJESHWARI 27 1 1 0 O 4 1 III N 24.8 9.6 B N 2.3 0.9 0.06 s 0 140 410 2.1
VICTORIA 34 2 2 1 P 5 1 IV N 24.6 8.6 N N 2.8 1.4 1.24 p 0 75 440 2.4
SHANTHI 39 0 0 0 M 7 1 V N 29.2 9.4 B N 2.7 1.6 2.4 p 0 120 400 3.1
LAKSHMI 45 2 2 0 O 6 1 IV N 23.4 11.2 N N 2.5 0.9 1.84 s 0 85 470 1.7
KANI 42 3 3 1 O 4 1 V N 25.4 9.6 N N 2.7 1.8 1.9 an 0 110 295 1.6
JOTHIBAI 39 2 2 0 O 5 1 V N 22.6 9.2 B Y(HYPO) 2 0.6 6.2 s 0 95 370 2.4
VIJAYAKUMARI 45 2 2 0 A 3 1 IV N 23.8 8.8 B N 3.1 1.9 4.2 atrophic 0 100 510 3.2
JEYALAKSHMI 43 4 3 0 M 6 2 V Y 24.2 8.6 N N 2.3 1.2 2.6 P 0 105 540 1.8
SHANTHI 45 2 3 0 M 3 1 IV N 25.6 9.4 N N 3.4 1.8 4.6 P 0 90 560 1.5
ANJALI 29 2 2 0 O 5 1 V N 24.8 10.2 B N 2.8 1.6 3.8 SDA 0 75 420 1.4
KUPPPU 38 2 2 0 M 6 1 V N 29.8 8.9 B Y(HYPO) 1.6 0.3 7.2 P 1 180 450 1.7
SHARMILA 26 1 1 0 A 4 1 III N 23.4 9.2 B N 2.6 1.2 2.4 An 0 85 480 2.1
BHAGIYAM 36 3 3 0 M 3 1 IV N 22.6 9 N N 2.8 1.6 3.6 P 0 170 270 2.6
JANAKI 32 2 2 0 O 4 1 IV N 28.4 9.8 B N 2.4 1.1 2.72 S 0 65 235 2.4
KAMALA 22 1 1 0 O 3 1 V N 28.6 9.2 N N 3.1 1.9 5.5 SDA 0 150 310 2.5
AMBIGAI 28 2 2 0 O 5 1 IV N 26.7 9.4 B N 2.3 0.9 1.8 S 0 105 250 1.8
SHAHJITHA BEGUM 24 2 2 0 P 4 1 V N 22.5 8.8 N N 2.8 1.7 2.6 P 0 140 280 1.6
HEMAVATHY 36 3 3 0 A 5 1 IV N 22.4 9.6 N N 2.4 1.01 2.2 p 0 65 510 1.2
NEELA 32 2 2 0 M 3 1 IV N 24.6 9.2 N N 2.7 1.12 2.95 P 0 185 370 1.8
UMA MAHESHWARI 26 1 1 0 M 5 1 V N 23.8 9 B Y(HYPO) 1.6 0.3 7.2 AN 1 75 400 2.6
PARIMAL 39 3 3 0 A 3 1 IV N 21.6 10.6 N N 2.8 1.2 2.86 s 0 145 350 1.5
SAKTHIESWARI 32 2 2 1 O 7 1 IV N 22.4 9.8 N N 2.58 1.12 2.6 P 0 95 260 1.6
MARAGADHAM 44 3 3 0 M 5 2 V N 24.2 8.4 N N 2.9 1.6 3.2 P 0 145 250 1.7
PALLAVI 22 1 1 0 O 4 1 III N 23.6 9.8 N N 2.4 0.92 2.54 S 0 105 512 3.4
KANNAGI 38 2 2 0 O 8 2 IV N 25.4 9.4 N N 2.82 1.6 2.94 S 0 135 375 4.1
CHELLAKILI 42 3 3 0 M 6 2 III N 28.6 8.8 N N 2.64 1.26 3.2 P 0 125 315 2.9
VANI 36 2 2 0 O 4 1 IV N 26.8 9 N N 2.9 1.01 2.7 S 0 115 285 3.4
JAGADEESWAR 28 1 1 0 O 6 1 V N 24.2 9.4 B N 2.2 1.16 2.42 S 0 60 375 1.9
GNAMMBAL 40 2 2 2 M 3 1 IV N 26.4 9.2 N N 2.3 1.84 2.78 p 0 180 355 1.5
SAKUNTHALA 34 2 2 0 M 5 1 IV N 26.3 8.8 N N 2.2 0.9 2.92 SDA 0 70 245 2.4
VANITHA 36 2 2 0 M 4 1 V N 24.6 9 N N 2.6 1.3 2.64 P 0 170 320 2.6
NIRMALA 34 2 2 0 A 5 1 IV Y 28.4 9.4 N N 3.2 1.84 3.26 s 0 80 520 3.5
KALAISELVI 37 3 3 0 O 6 1 V N 29.4 8.4 N N 2.5 1.21 0.84 S 1 160 290 2.8
KARPAGAM 40 2 2 0 O 12 1 IV N 24.6 8.9 B N 2.74 1.48 3 S 0 90 480 4.1
JANAKI 36 2 2 0 M 6 1 V N 25.3 9.2 N N 2.68 1.6 2.84 P 0 150 520 2.3
SARASWATHY 29 2 2 0 M 3 1 IV N 25.8 9.8 N N 2.4 1.2 1.46 AN 0 100 340 1.8
RENGANAYAGI 38 2 2 0 M 4 2 V N 28.6 8.6 B Y(HYPO) 1.2 0.3 6.42 P 0 140 350 4.1
ESTHER 32 2 3 0 M 6 1 V N 28.6 7.9 N N 2.72 1.04 2.38 P 0 110 410 2.8
RUKMANI 36 3 2 1 M 5 1 V N 24.8 8.8 N N 2.46 1.28 2.54 SDA 0 130 510 1.5
KALAVATHY 28 2 2 0 O 6 1 III N 26.8 9.4 N N 2.72 1.36 2.82 S 0 110 240 2.4
KALPANA 32 2 22 1 A 4 1 IV N 24.2 8.4 N N 2.46 1.02 2.48 P 0 120 245 1.9
VIJAYA 35 3 3 0 M 6 1 V N 28.4 8.9 B N 2.9 1.67 2.8 P 0 85 310 2.6
SEETHA 29 2 2 0 M 3 1 IV N 28.6 9.6 N N 2.48 1.16 2.72 P 0 65 260 3.1
RADHA 34 2 2 0 M 7 2 V N 26.4 8.2 B N 2.96 1.82 3.2 AN 0 125 280 1.8
VELLAMMAL 37 2 2 0 M 6 1 IV N 23.2 8.6 N N 2.84 1.62 2.78 P 0 135 510 2.3
SHENBAGAM 30 1 1 0 A 5 1 IV N 22.6 9.2 N N 2.72 1.56 2.96 AN 0 175 360 1.9
CHINNAPONNU 40 4 4 0 M 6 2 V N 25.4 8.2 B N 2.98 1.64 3.4 P 0 65 270 2.8
REKHA 28 2 2 0 M 4 1 III N 27.6 9.4 N N 2.46 1.04 2.64 P 0 85 250 2.5
MAHESWARI 39 2 2 0 M 6 1 IV N 29.4 9 B N 2.38 1.06 1.84 Hyperplasia cystic0 90 160 1.6
PRIYA 27 1 1 0 M 4 1 IV N 28.4 8.8 N N 2.42 0.96 1.62 P 0 120 150 2.4
VALLI 42 3 3 0 M 6 2 V N 26.6 8.2 N N 3.02 1.54 2.84 hyperplasia adenomatous0 180 180 2.6
  
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 

